Haemonetics Corporation (HAE)

Market Cap	3.50B +7.3%
Revenue (ttm)	1.33B -2.0%
Net Income	97.31M -42.0%
EPS	2.05 -38.1%
Shares Out	45.45M
PE Ratio	37.52
Forward PE	14.74
Dividend	n/a
Ex-Dividend Date	n/a

Volume	886,426
Open	77.95
Previous Close	78.20
Day's Range	75.93 - 78.43
52-Week Range	47.32 - 87.32
Beta	0.54
Analysts	Buy
Price Target	83.10 (+8.05%)
Earnings Date	May 7, 2026

About HAE

Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions. The company operates through Plasma, Blood Center, and Hospital segments. It provides automated plasma collection systems, donor management software, and supporting software solutions, such as NexSys PCS plasmapheresis equipment system and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management syst...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: May 9, 1991
• Employees: 3,009
• Stock Exchange: NYSE
• Ticker Symbol: HAE
• Website: https://www.haemonetics.com

Financial Performance

In fiscal year 2026, Haemonetics's revenue was $1.33 billion, a decrease of -1.97% compared to the previous year's $1.36 billion. Earnings were $97.31 million, a decrease of -41.97%.

Analyst Summary

According to 11 analysts, the average rating for HAE stock is "Buy." The 12-month stock price target is $83.1, which is an increase of 8.05% from the latest price.

Price Target

$83.1

(8.05% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Jun 16, 2026

Data Sources Report a data error